Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients

Author： Yoon Dok  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.30, Iss.2, 2012-04, pp. : 819-827

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate

By Shirao Kuniaki   Nishida Toshirou   Doi Toshihiko   Komatsu Yoshito   Muro Kei   Li Yinhua   Ueda Eiji   Ohtsu Atsushi  

Investigational New Drugs, Vol. 28, Iss. 6, 2010-12 ,pp. : 866-875

Springer Publishing Company

Access to resources Recommend Favorite

Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Entérologues Oncologues

By Brieau Bertrand   Dahan Laetitia   De Rycke Yann   Boussaha Tarek   Vasseur Philippe   Tougeron David   Lecomte Thierry   Coriat Romain   Bachet Jean-Baptiste   Claudez Pierre   Zaanan Aziz   Soibinet Pauline   Desrame Jérome   Thirot-Bidault Anne   Trouilloud Isabelle   Mary Florence   Marthey Lysiane   Taieb Julien   Cacheux Wulfran   Lièvre Astrid  

Cancer, Vol. 121, Iss. 18, 2015-09 ,pp. : 3290-3297

Blackwell Publishing

Access to resources Recommend Favorite

Second-line drug therapy for osteoarthritis

By Brandt Kenneth D  

Clinical Medicine, Vol. 1, Iss. 2, 2001-03 ,pp. : 110-112

Royal College Of Physicians

Access to resources Recommend Favorite

A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma

By Li Ning   Ou Wei   Yang Hua   Liu Qian-Wen   Zhang Song-Liang   Wang Bao-Xiao   Wang Si-Yu  

Cancer, Vol. 120, Iss. 9, 2014-05 ,pp. : 1379-1386

Blackwell Publishing

Access to resources Recommend Favorite

Lenalidomide plus dexamethasone a winner as second-line therapy

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 645, 2012-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite